RT Journal Article
SR Electronic
T1 Exploiting convergent evolution to derive a pan-cancer cisplatin sensitivity gene expression signature
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.10.21265799
DO 10.1101/2021.11.10.21265799
A1 Jessica A. Scarborough
A1 Steven A. Eschrich
A1 Javier Torres-Roca
A1 Andrew Dhawan
A1 Jacob G. Scott
YR 2021
UL http://medrxiv.org/content/early/2021/11/11/2021.11.10.21265799.abstract
AB Precision medicine offers remarkable potential for the treatment of cancer, but is largely focused on tumors that harbor actionable mutations. Gene expression signatures can expand the scope of precision medicine by predicting response to traditional (cytotoxic) chemotherapy agents without relying on changes in mutational status. We present a novel signature extraction method, inspired by the principle of convergent evolution, which states that tumors with disparate genetic backgrounds may evolve similar phenotypes independently. This evolutionary-informed method can be utilized to produce signatures predictive of response to over 200 chemotherapeutic drugs found in the Genomics of Drug Sensitivity in Cancer Database. Here, we demonstrate its use by extracting the Cisplatin Response Signature, CisSig, for use in predicting a common trait (sensitivity to cisplatin) across disparate tumor subtypes (epithelial-origin tumors). CisSig is predictive of cisplatin response within the cell lines and clinical trends in independent datasets of tumor samples. This novel methodology can be used to produce robust signatures for the prediction of traditional chemotherapeutic response, dramatically increasing the reach of personalized medicine in cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the following NIH grants: 5R37CA244613-02, T32GM007250, and 1F30CA257076-01. Additionally, it was funded by the American Cancer Society (RSG-20-096-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Genomics of Drug Sensitivity in Cancer (GDSC) dataset was accessed using R (code in the cited GitHub repository) to directly download files from the following links, which do not require registration: https://www.cancerrxgene.org/gdsc1000/GDSC1000_WebResources//Data/preprocessed/Cell_line_RMA_proc_basalExp.txt.zip, ftp://ftp.sanger.ac.uk/pub/project/cancerrxgene/releases/current_release/GDSC2_fitted_dose_response_25Feb20.xlsx, ftp://ftp.sanger.ac.uk/pub/project/cancerrxgene/releases/current_release/Cell_Lines_Details.xlsx. The Cancer Genome Atlas (TCGA) dataset was accessed using the `RTCGAToolbox` R package (code in the cided GitHub repository) to download each disease site's RSEM normalized RNASeq V2 (labeled `RNASeq2GeneNorm`). The data can be accessed, without registration here: https://gdac.broadinstitute.org/. The Total Cancer Care (TCC) dataset requires application for access, and can be found here: https://moffitt.org/research-science/total-cancer-care/. Approval was received to use the anonymized data in this manuscript after registration, and the IRB of Moffitt Cancer Center gave ethical approval for the collection of the original data. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced can be accessed by following code available online at https://github.com/jessicascarborough/cissig https://github.com/jessicascarborough/cissig